# Patellar resurfacing as a prognostic variable in total knee arthroplasty: a two‑decade retrospective cohort (2000‑2020)

**Authors:** Diego Laverde Osorio, Luis David Marcial Barba, Nelva Garduza Leyva, Efrain Diaz Borjon, Juan Montejo Vargas, Georges Jirjis Makdissy Salomon, Christian Hazel Hernandez Romero

PMC · DOI: 10.1186/s12891-025-09076-y · BMC Musculoskeletal Disorders · 2026-01-13

## TL;DR

This study found that patellar resurfacing during knee replacement surgery reduces pain and loosening risks without increasing overall revision rates.

## Contribution

The study provides long-term evidence supporting selective patellar resurfacing over routine use in knee arthroplasty.

## Key findings

- Patellar resurfacing reduced anterior knee pain by 83% compared to non-resurfacing.
- Resurfacing lowered aseptic loosening risk by 7.5% without increasing revision rates.
- No significant difference in overall revision rates between resurfaced and non-resurfaced groups.

## Abstract

The impact of patellar resurfacing (PR) on long-term outcomes following primary total knee arthroplasty (TKA) remains a topic of debate.

This study examined a retrospective cohort of 334 primary total knee arthroplasties (TKAs) performed between 2000 and 2020 at a specialized hospital. The surgeries were conducted from January 2000 to December 2020, allowing for a maximum potential follow-up period of 20 years. The primary endpoint assessed was the rate of any-cause revision. Secondary endpoints included anterior knee pain, aseptic loosening, patient-reported outcomes (Western Ontario and McMaster Universities Osteoarthritis index and Oxford Knee Score), and complications. Kaplan-Meier estimates and multivariable Cox models, adjusted for age, body mass index, and inflammatory arthropathy, were utilized.

PR yielded an absolute risk reduction (ARR) of 83% for anterior knee pain (2.2% in the PR group vs. 85.2% in the WPR group; number needed to treat ≈ 1–2) and an ARR of 7.5% for aseptic loosening (4.4% vs. 11.9%; NNT = 14). The overall revision rates were 5.1% for PR and 6.7% for WPR, demonstrating no significant differences (hazard ratio 0.65, 95% confidence interval 0.30–1.42).

Patellar resurfacing significantly alleviates anterior knee pain and decreases the risk of aseptic loosening without raising the overall revision rate. These findings advocate for a selective resurfacing approach targeting patellae at a higher risk of pain rather than adopting a routine or universal resurfacing strategy.

Not applicable, this study is an observational retrospective cohort; no prospective registration was required.

The online version contains supplementary material available at 10.1186/s12891-025-09076-y.

## Full-text entities

- **Genes:** SPNS1 (SPNS lysolipid transporter 1, lysophospholipid) [NCBI Gene 83985] {aka HSpin1, LAT, PP2030, SLC62A1, SLC63A1, SPIN1}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** RA (MESH:D001172), Fracture of the patella (MESH:D000092462), inflammatory arthritis (MESH:D001168), TKA (MESH:D007718), Aseptic loosening (MESH:D011475), hip osteoarthritis (MESH:D015207), angular deformity (MESH:D065170), death (MESH:D003643), infection (MESH:D007239), rheumatic (MESH:D012216), rheumatologic pathologies (MESH:D005598), septic (MESH:D001170), instability (MESH:D043171), dislocation (MESH:D004204), degenerative joint pathology (MESH:D019636), complication (MESH:D008107), inflammation (MESH:D007249), PR (MESH:D031222), Pain (MESH:D010146), fracture (MESH:D050723), rupture of the quadricipital tendon (MESH:D012421), patellar osteonecrosis (MESH:D010020), adrenal insufficiency (MESH:D000309), postoperative pain (MESH:D010149), KSS (MESH:D007625), inflammatory rheumatic pathologies (MESH:D012213), ACL (MESH:D000070598), obesity (MESH:D009765), anterior knee pain (MESH:D046788), gait disturbance (MESH:D020233), overweight (MESH:D050177), ankylosing spondylitis (MESH:D013167), OA (MESH:D010003), joint wear and tear (MESH:D057085), cartilage damage (MESH:D002357), anterior pain (MESH:D019547), SLE (MESH:D008180), periprosthetic infection (MESH:D057068), 3-4 (MESH:D053307)
- **Chemicals:** MCONTROL-2459/2024 (-), hydroxychloroquine (MESH:D006886), methotrexate (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12801448/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12801448/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12801448/full.md

---
Source: https://tomesphere.com/paper/PMC12801448